CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers
- PMID: 31707664
- DOI: 10.1007/978-1-0716-0146-4_1
CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers
Abstract
Immunotherapy has been growing in the past decade as a therapeutic alternative for cancer treatment. In this chapter, we deal with CAR-T cells, genetically engineered autologous T cells to express a chimeric receptor specific for an antigen expressed on tumor cell surface. While this type of personalized therapy is revolutionizing cancer treatment, especially B cell malignancies, it has some challenging limitations. Here, we discuss the basic immunological and technological aspects of CAR-T cell therapy, the limitations that have compromised its efficacy and safety, and the current proposed strategies to overcome these limitations, thereby allowing for greater therapeutic application of CAR-T cells.
Keywords: CAR-T cells; Chimeric antigen receptor; Immunotherapy; T cells.
Similar articles
-
Immunobiology of chimeric antigen receptor T cells and novel designs.Immunol Rev. 2019 Jul;290(1):100-113. doi: 10.1111/imr.12794. Immunol Rev. 2019. PMID: 31355496 Review.
-
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3. Mol Cancer. 2018. PMID: 29329591 Free PMC article. Review.
-
CAR T-cell therapy: Full speed ahead.Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591. Hematol Oncol. 2019. PMID: 31187533 Review.
-
Advances in off-the-shelf CAR T-cell therapy.Clin Adv Hematol Oncol. 2019 Mar;17(3):155-157. Clin Adv Hematol Oncol. 2019. PMID: 30969953 No abstract available.
-
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.Mol Cancer. 2019 Aug 20;18(1):125. doi: 10.1186/s12943-019-1057-4. Mol Cancer. 2019. PMID: 31429760 Free PMC article. Review.
Cited by
-
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer.Vaccines (Basel). 2023 Dec 7;11(12):1826. doi: 10.3390/vaccines11121826. Vaccines (Basel). 2023. PMID: 38140230 Free PMC article.
-
Editorial: Non-cellular immunotherapies in pediatric malignancies.Front Immunol. 2024 Feb 21;15:1379278. doi: 10.3389/fimmu.2024.1379278. eCollection 2024. Front Immunol. 2024. PMID: 38449864 Free PMC article. No abstract available.
-
ROR1-targeting switchable CAR-T cells for cancer therapy.Oncogene. 2022 Aug;41(34):4104-4114. doi: 10.1038/s41388-022-02416-5. Epub 2022 Jul 20. Oncogene. 2022. PMID: 35859167 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous